Navigation Links
Boehringer Ingelheim Unveils Diabetes Pipeline
Date:6/6/2009

eline to week 12.(1) Out of the 333 randomized patients, 268 patients received double-blind treatment with linagliptin (1 mg, n=65; 5 mg, n=66; 10 mg, n=66) or placebo.(1) An open-label arm with 65 patients on glimepiride was added for descriptive control.(1)

Additional results from the study

The addition of linagliptin to metformin treatment for 12 weeks resulted in clinically relevant and statistically significant reductions in HbA1c and fasting blood sugar or fasting plasma glucose (FPG) levels (p-values of less than 0.05%):(1)

  • Statistically significant reductions in mean HbA1c levels with linagliptin 5 mg and 10 mg compared with metformin alone (both p<0.001) were observed from week four though week 12.(1)
  • In addition, all linagliptin doses showed significant reductions in FPG levels compared with metformin alone (placebo-corrected mean changes from baseline; -19.2 mg/dL for 1 mg, -34.7 mg/dL for 5 mg, and -29.0 mg/dL for 10 mg).(1)
  • In the open-label comparator arm, the placebo-corrected mean change from baseline in HbA1c was -0.90 percent.(1)
  • More than 85% of the patients receiving the 5mg and 10mg doses of linagliptin demonstrated greater that or equal to 80% DPP-4 inhibition at trough at week 12(1)
  • HbA1c reductions of at least 0.5 percent were achieved in 44 percent to 53 percent of patients on linagliptin, but only in 13 percent of the patients receiving metformin alone.(1)

About type 2 diabetes

There are approximately 23.6(5) million Americans and 246 million people worldwide(6) with diabetes. Type 2 diabetes is the most common type of diabetes accounting for more than 90% of all diabetes cases in the developed world.(7) Every ten seconds two people develop diabetes and one person dies from diabetes-related causes around the world.(6) Each
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
4. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
5. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
6. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
7. NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting
8. Oregon Tourism Commission Unveils New Online Customer Service Training Program
9. AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
10. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
11. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
(Date:7/30/2015)... ... July 30, 2015 , ... As more hospitals across ... of recruiting patients becomes a serious challenge. Because of growing competition, it is ... within the local community. , The team at Wound Care Advantage ...
(Date:7/30/2015)... ... July 30, 2015 , ... OSF Healthcare System has been ... Most Wired Survey conducted by Hospitals & Health Networks. This marks the fourth consecutive ... by The Sisters of the Third Order of St. Francis . , Health ...
(Date:7/30/2015)... ... ... a healthy head of hair and a feeling of confidence is a powerful one for ... a devastating impact on the daily life of a person. From increased anxiety to ... loss are not to be taken lightly. , The skilled staff at Parsa Mohebi Hair ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca Life has created ... With no water needed, the refreshing berry-flavored tablets are the perfect travel companion. ... natural ingredients that may help with body detoxification, protection and hydration,” said Mark ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... TikiLIVE, has worked to protect victims in San Diego, California’s Gaslamp Quarter Plaza ... used by Gaslamp Quarter Plaza actively monitor the area for any suspicious activity. ...
Breaking Medicine News(10 mins):Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3
... United States, the management of glaucoma costs about $2.5 ... costs, glaucoma medications account for an estimated 38% to ... the January 2008 issue of the American Journal of ... Science Center College of Medicine, Temple, Texas; analyzed the ...
... Advice for Doctors About Low-Fat, Low-Carb Restricted Diets ... The American,Diabetes Association (ADA) today issued its ... treat people with diabetes,using the most current evidence ... in the Medical Nutrition Therapy,section dealing with weight ...
... Arcade for Kids, Teens, and Adult Gamers --, ... ft. Mega-Center officially opened for workouts on December 17, ... off Cincinnati-Dayton,Road & I-75 next to Wal-Mart. A month ... a silent auction on Saturday, January,19th from 5pm-8pm to ...
... more likely to broach the topic with patients than ... (HealthDay News) -- Many doctors avoid issues of spirituality ... true for most psychiatrists, a new study finds. , ... said it,s always or usually appropriate to ask patients ...
... Dec. 27 Eclipsys Corporation(R),(Nasdaq: ECLP ), ... in the 2008 JPMorgan Healthcare Conference taking place ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050209/FLW006LOGO ), Eclipsys ... January,8th at 3:00 p.m. Pacific time. To access ...
... 27 The dental group that operates the,Park ... today,that it has settled litigation with its administrative ... Minnesota subsidiary,PDHC, Ltd., On December 14, 2007, ... known as PDG, P.A., and Dental Specialists of ...
Cached Medicine News:Health News:Cost of glaucoma medications may impact treatment 2Health News:ADA Issues New Clinical Practice Recommendations 2Health News:ADA Issues New Clinical Practice Recommendations 3Health News:Fitworks West Chester Mega-Center Now Open 2Health News:Fitworks West Chester Mega-Center Now Open 3Health News:Most Psychiatrists Open to Discussing Spiritual Concerns 2Health News:Most Psychiatrists Open to Discussing Spiritual Concerns 3Health News:Eclipsys to Present at JPMorgan Healthcare Conference 2Health News:Eclipsys to Present at JPMorgan Healthcare Conference 3Health News:Park Dental Doctor Group Settles Litigation With Service Provider 2
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
Medicine Products: